Translations:Dulaglutide/18/en: Difference between revisions

From Azupedia
Jump to navigation Jump to search
VisualWikitext
FuzzyBot (talk | contribs)
14,944 edits
Importing a new version from external source
 
(No difference)

Latest revision as of 10:29, 12 February 2024

Information about message (contribute)
This message has no documentation. If you know where or how this message is used, you can help other translators by adding documentation to this message.
Message definition (Dulaglutide)
The U.S. [[Food and Drug Administration]] (FDA) approved dulaglutide with a [[Risk Evaluation and Mitigation Strategies|Risk Evaluation and Mitigation Strategy]] (REMS), and granted the approval of Trulicity to [[Eli Lilly and Company]]. The REMS consists of a number of steps that Eli Lilly will take to make physicians aware of the risk of pancreatitis and the potential risk of [[medullary thyroid carcinoma]]  associated with the drug.

The U.S. Food and Drug Administration (FDA) approved dulaglutide with a Risk Evaluation and Mitigation Strategy (REMS), and granted the approval of Trulicity to Eli Lilly and Company. The REMS consists of a number of steps that Eli Lilly will take to make physicians aware of the risk of pancreatitis and the potential risk of medullary thyroid carcinoma associated with the drug.

Retrieved from "https://wiki.tiffa.net/w/index.php?title=Translations:Dulaglutide/18/en&oldid=113618"